Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Use of leflunomide in patients with chronic hypersensitivity pneumonitis

Fig. 4

Trajectory of pulmonary function before and after LEF treatment in patients with fibrosis > 20%. a FVC decline of 0.037 ± 2.31% (SEM) predicted/year was reversed to an increase of 1.85 ± 4.54% predicted/year with treatment. However, FVC% predicted did not improve significantly at 12 months (mean increase 1.9%predicted; 95% CI, − 5.5 to 9.3%; p = 0.610). b The DLCO slope did not change significantly with treatment (p = 0.456). DLCO% predicted did not change significantly at 12 months (mean decrease 3.8%predicted; 95% CI, − 2.4 to 10.0%; p = 0.228)

Back to article page